

Amandine Hurbin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7436932/publications.pdf>

Version: 2024-02-01

51
papers

1,889
citations

236612

25
h-index

253896

43
g-index

59
all docs

59
docs citations

59
times ranked

3165
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor-Specific Imaging with Angiostamp800 or Bevacizumab-IRDye 800CW Improves Fluorescence-Guided Surgery over Indocyanine Green in Peritoneal Carcinomatosis. <i>Biomedicines</i> , 2022, 10, 1059.	1.4	2
2	Quantitative Proteomic Approach Reveals Altered Metabolic Pathways in Response to the Inhibition of Lysine Deacetylases in A549 Cells under Normoxia and Hypoxia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3378.	1.8	3
3	Analysis of Astroglial Secretomic Profile in the Mecp2-Deficient Male Mouse Model of Rett Syndrome. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4316.	1.8	7
4	Photodynamic Diagnosis and Therapy for Peritoneal Carcinomatosis: Emerging Perspectives. <i>Cancers</i> , 2020, 12, 2491.	1.7	17
5	Stapled peptide targeting the CDK4/Cyclin D interface combined with Abemaciclib inhibits KRAS mutant lung cancer growth. <i>Theranostics</i> , 2020, 10, 2008-2028.	4.6	15
6	Verteporfin-Loaded Lipid Nanoparticles Improve Ovarian Cancer Photodynamic Therapy In Vitro and In Vivo. <i>Cancers</i> , 2019, 11, 1760.	1.7	64
7	A large scale proteome analysis of the gefitinib primary resistance overcome by KDAC inhibition in KRAS mutated adenocarcinoma cells overexpressing amphiregulin. <i>Journal of Proteomics</i> , 2019, 195, 114-124.	1.2	10
8	Current trends in protein acetylation analysis. <i>Expert Review of Proteomics</i> , 2019, 16, 139-159.	1.3	51
9	The pyrrolopyrimidine colchicine-binding site agent PP-13 reduces the metastatic dissemination of invasive cancer cells in vitro and in vivo. <i>Biochemical Pharmacology</i> , 2019, 160, 1-13.	2.0	17
10	Anti-tumor efficacy of hyaluronan-based nanoparticles for the co-delivery of drugs in lung cancer. <i>Journal of Controlled Release</i> , 2018, 275, 117-128.	4.8	63
11	Nuclear translocation of IGF1R by intracellular amphiregulin contributes to the resistance of lung tumour cells to EGFR-TKI. <i>Cancer Letters</i> , 2018, 420, 146-155.	3.2	20
12	Systemic Delivery of Tumor-Targeted Bax-Derived Membrane-Active Peptides for the Treatment of Melanoma Tumors in a Humanized SCID Mouse Model. <i>Molecular Therapy</i> , 2017, 25, 534-546.	3.7	18
13	Plasma Circulating Tumor DNA Levels for the Monitoring of Melanoma Patients: Landscape of Available Technologies and Clinical Applications. <i>BioMed Research International</i> , 2017, 2017, 1-8.	0.9	39
14	Tubulin Beta-3 Chain as a New Candidate Protein Biomarker of Human Skin Aging: A Preliminary Study. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-21.	1.9	16
15	Identification of pyrrolopyrimidine derivative PP-13 as a novel microtubule-destabilizing agent with promising anticancer properties. <i>Scientific Reports</i> , 2017, 7, 10209.	1.6	16
16	Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6843-6855.	1.0	30
17	LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers. <i>Cancer Research</i> , 2016, 76, 3541-3552.	0.4	28
18	Nuclear translocation of IGF-1R by amphiregulin: a regulator of the response of lung adenocarcinoma to EGFR-TKI?. <i>European Journal of Cancer</i> , 2016, 61, S125.	1.3	2

#	ARTICLE	IF	CITATIONS
19	Identification of a pyrrolo-pyrimidin derivative to overcome the resistance to apoptosis in non-small cell lung cancer cells. <i>European Journal of Cancer</i> , 2016, 61, S140.	1.3	0
20	Near-infrared fluorescence imaging-guided surgery improves recurrence-free survival rate in novel orthotopic animal model of head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, E246-55.	0.9	33
21	Targeting CD44 receptor-positive lung tumors using polysaccharide-based nanocarriers: Influence of nanoparticle size and administration route. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016, 12, 921-932.	1.7	45
22	Rôle de l'imagerie de fluorescence proche infrarouge dans la résection des adénopathies métastatiques dans un modèle animal orthotopique optimisé des cancers des VADS. <i>Annales Francaises D'Oto-Rhino-Laryngologie Et De Pathologie Cervico-Faciale</i> , 2015, 132, 312-317.	0.0	0
23	Polysaccharide-based nanocarriers targeting CD44 for lung cancer treatment. <i>Revue Des Maladies Respiratoires</i> , 2015, 32, 323.	1.7	0
24	High throughput screening to identify new compounds with proapoptotic activity in resistant lung cancer cells. <i>Revue Des Maladies Respiratoires</i> , 2015, 32, 324.	1.7	0
25	A miniaturized imaging system for optical guided surgery of head and neck cancer. <i>Proceedings of SPIE</i> , 2015, , .	0.8	0
26	Role of near-infrared fluorescence imaging in the resection of metastatic lymph nodes in an optimized orthotopic animal model of HNSCC. <i>European Annals of Otorhinolaryngology, Head and Neck Diseases</i> , 2015, 132, 337-342.	0.4	10
27	Role of near-infrared fluorescence imaging in head and neck cancer surgery: from animal models to humans. <i>European Archives of Oto-Rhino-Laryngology</i> , 2015, 272, 2593-2600.	0.8	27
28	A Recombinant Fungal Lectin for Labeling Truncated Glycans on Human Cancer Cells. <i>PLoS ONE</i> , 2015, 10, e0128190.	1.1	25
29	Abstract 5399: Anti-cancer activity of a new LIM-Kinases inhibitor: "LIM-Pyr1", 2015, , .		0
30	The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism. <i>International Journal of Cancer</i> , 2014, 134, 2560-2571.	2.3	50
31	Quantitative Proteomic Approach to Understand Metabolic Adaptation in Non-Small Cell Lung Cancer. <i>Journal of Proteome Research</i> , 2014, 13, 4695-4704.	1.8	28
32	495: AKT and gefitinib resistance in mutant KRAS non-small cell lung cancers through mechanisms dependent of acetylation. <i>European Journal of Cancer</i> , 2014, 50, S119.	1.3	0
33	792: Polysaccharide-based nanocarriers targeting CD44 for lung cancer treatment. <i>European Journal of Cancer</i> , 2014, 50, S191.	1.3	1
34	Targeted delivery of a proapoptotic peptide to tumors <i>in vivo</i> . <i>Journal of Drug Targeting</i> , 2011, 19, 582-588.	2.1	27
35	The multiple roles of amphiregulin in human cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2011, 1816, 119-131.	3.3	148
36	Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma. <i>Journal of Pathology</i> , 2011, 225, 83-95.	2.1	43

#	ARTICLE	IF	CITATIONS
37	101: Identification of differential pathways in mucinous and non-mucinous subtypes of lung adenocarcinoma suggested new therapeutic strategies. <i>Bulletin Du Cancer</i> , 2010, 97, S81-S82.	0.6	2
38	Amphiregulin Promotes BAX Inhibition and Resistance to Gefitinib in Non-small-cell Lung Cancers. <i>Molecular Therapy</i> , 2010, 18, 528-535.	3.7	49
39	Amphiregulin Promotes Resistance to Gefitinib in NonSmall Cell Lung Cancer Cells by Regulating Ku70 Acetylation. <i>Molecular Therapy</i> , 2010, 18, 536-543.	3.7	38
40	210 Identification and characterization of amphiregulin as a new biomarker of resistance to gefitinib in non-small cell lung cancers. <i>European Journal of Cancer, Supplement</i> , 2010, 8, 55.	2.2	0
41	Clustering and Internalization of Integrin $\alpha_5\beta_1$ With a Tetrameric RGD-synthetic Peptide. <i>Molecular Therapy</i> , 2009, 17, 837-843.	3.7	148
42	The increasing role of amphiregulin in non-small cell lung cancer. <i>Pathologie Et Biologie</i> , 2009, 57, 511-512.	2.2	14
43	Cooperation of Amphiregulin and Insulin-like Growth Factor-1 Inhibits Bax- and Bad-mediated Apoptosis via a Protein Kinase C-dependent Pathway in Non-small Cell Lung Cancer Cells. <i>Journal of Biological Chemistry</i> , 2005, 280, 19757-19767.	1.6	38
44	Inhibition of Apoptosis by Amphiregulin via an Insulin-like Growth Factor-1 Receptor-Dependent Pathway in Non-Small Cell Lung Cancer Cell Lines. <i>Annals of the New York Academy of Sciences</i> , 2003, 1010, 354-357.	1.8	23
45	Inhibition of Apoptosis by Amphiregulin via an Insulin-like Growth Factor-1 Receptor-dependent Pathway in Non-small Cell Lung Cancer Cell Lines. <i>Journal of Biological Chemistry</i> , 2002, 277, 49127-49133.	1.6	82
46	Side-effects of a systemic injection of linear polyethylenimine-DNA complexes. <i>Journal of Gene Medicine</i> , 2002, 4, 84-91.	1.4	363
47	Expression of the Genes Encoding the Vasopressin-Activated Calcium-Mobilizing Receptor and the Dual Angiotensin II/Vasopressin Receptor in the Rat Central Nervous System. <i>Journal of Neuroendocrinology</i> , 2001, 12, 677-684.	1.2	26
48	Cell cycle arrest is sufficient for p53-mediated tumor regression. <i>Gene Therapy</i> , 2001, 8, 1705-1712.	2.3	19
49	Caffeine Sensitizes Human H358 Cell Line to p53-mediated Apoptosis by Inducing Mitochondrial Translocation and Conformational Change of BAX Protein. <i>Journal of Biological Chemistry</i> , 2001, 276, 38980-38987.	1.6	40
50	Pharmacological characterization of volume-sensitive, taurine permeable anion channels in rat supraoptic glial cells. <i>British Journal of Pharmacology</i> , 2000, 130, 1976-1982.	2.7	55
51	The V_{1a} and V_{1b} , But Not V_{2} , Vasopressin Receptor Genes Are Expressed in the Supraoptic Nucleus of the Rat Hypothalamus, and the Transcripts Are Essentially Colocalized in the Vasopressinergic Magnocellular Neurons. <i>Endocrinology</i> , 1998, 139, 4701-4707.	1.4	89